Karin Haider
A 24 week, randomized, double-blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in pulmonary arterial hypertension (PAH)
01.02.2012
Klinische Forschung - 01.02.2012 - 01.04.2014
Abgebrochen
Projektleitung: Brutsche Martin
Mitarbeiter/innen: Burger Barbara, Haider Karin
The obstructive pulmonary disease outcomes cohort of Switzerland (TOP DOCS): phenotypes and vascular amage in COPD
01.01.2012Prospective cohort study including COPD patients from 6 study centers in Northern Switzerland
Grundlagenforschung - 01.01.2012 - 31.12.2015
Automatisch geschlossen
Projektleitung: Brutsche Martin
Mitarbeiter/innen: Rüdiger Jochen, Burger Barbara, Haider Karin
A multicenter, double-blind, placebo-controlled phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension
01.10.2009The primary objective is to demonstrate the effect of ACT-293987 on time to first clinical worsening in patients with pulmonary arterial hypertension (PAH)
Klinische Forschung - 01.10.2009 - 01.04.2013
Abgebrochen
Projektleitung: Brutsche Martin
Mitarbeiter/innen: Burger Barbara, Haider Karin, Rüdiger Jochen
A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150ug o.d. vs inhaled tiotropium 18ug o.d. on lung function, rate of exacerbations and related outcomes in patients with COPD
01.07.2009
Klinische Forschung - 01.07.2009 - 01.07.2011
Abgeschlossen
Projektleitung: Brutsche Martin
Mitarbeiter/innen: Haider Karin, Burger Barbara